<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479543</url>
  </required_header>
  <id_info>
    <org_study_id>SETOPROB</org_study_id>
    <nct_id>NCT01479543</nct_id>
  </id_info>
  <brief_title>Effects of Probiotics in Immune System of Healthy Adults</brief_title>
  <acronym>SETOPROB</acronym>
  <official_title>Colonization, Safety, Tolerance, and Effects of Three Probiotic Strains on the Immune System of Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hero Institute for Infant Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hero Institute for Infant Nutrition</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present report describes the design of a clinical trial performed on healthy adult
      individuals to check whether the daily intake of the new Hero strains contribute to
      intestinal colonization, under safe and tolerable conditions, with a positive contribution to
      health and wellbeing of healthy individuals.

      Daily intake of one or several probiotic strains, (CNCM I-4034, CNCM I-4035, CNCM I-4036),
      increases intestinal microbiota in healthy adults, being safe and well tolerated. The regular
      intake has positive effects on the gastrointestinal and immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project will be based on a double-blind, randomized, and placebo-controlled clinical
      trial. It will be multi-Centre, with four groups plus a control group.

      The colonization performed by the strains and the modification of the intestinal microbiota
      will be evaluated by means of strain identification with RT-PCR equipped with specific
      primers, and bacterial population counting with in situ immunofluorescence techniques.

      The safety of strain intake will be evaluated with physical examination, blood parameters,
      and test son faeces to check for resistance to ampicillin and tetracycline by lactic flora.

      Tolerance will be evaluated by means of the record of gastrointestinal symptoms and the
      record of aspect and frequency of faeces.

      The effect on the systemic and adaptive immune system will be measured by means of lymphocyte
      populations and plasma cytokine present on blood, IgAs on serum, saliva and faeces. Also AGCC
      on faeces.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Tolerance After Probiotic Consumption.</measure>
    <time_frame>4 weeks of the treatments. Daily recorded.</time_frame>
    <description>Tolerance of these probiotic strains was determined using the gastrointestinal symptom rating scale (GSRS), daily recorded gastrointestinal symptoms and defecation frequency.Intolerance was defined as a symptom score of 2 or higher on the GSRS. The unit of measure is the &quot;number of participants&quot; was tolerant to the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal and Immune Effects of Probiotics Consumption.</measure>
    <time_frame>At Time zero, after 4 weeks, and 2 later.</time_frame>
    <description>Effect on the systemic and adaptive immune system. This will be measured by means of lymphocite populations and plasma cytokine present on blood, IgAs on serum (at zero time and after four weeks of treatment), IgAs on saliva and faeces and AGCC (at zero time and after four weeks and two more weeks).
Gastrointestinal effects will be measured by means of gastrointestinal symptoms record and frequency and aspect of faeces, during the treatment and the following two weeks (wash-out period).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Conditions Influencing Health Status</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers received Probiotic CNCM I-4034.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive Probiotic CNCM I-4035.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers are given Probiotic CNCM I-4036.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers receive a Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic CNCM I-4034</intervention_name>
    <description>Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>CNCM I-4034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic CNCM I-4035</intervention_name>
    <description>9x10E9 cfu (colony forming unit) per day during 28 days.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>CNCM I-4035</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic CNCM I-4036</intervention_name>
    <description>9x10E9 cfu (colony forming unit) per day during 28 days.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>CNCM I-4036</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotics CNCM I-4035 and CNCM I-4036</intervention_name>
    <description>9x10E9 cfu (colony forming unit) per day during 28 days.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>CNCM I-4035+CNCM I-4036</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule for 28 days.</description>
    <arm_group_label>Group E</arm_group_label>
    <other_name>Placebo, group E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult

          -  Age: 18-50 years

          -  Normal defecation

          -  Normal blood parameters

          -  Body Mass Index: 18-30

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Antibiotic treatment

          -  Gastrointestinal disease

          -  Diarrhoea

          -  Constipation

          -  Diabetes

          -  Abnormal blood pressure

          -  Allergy

          -  Smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Abell√°n, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hero Institute of Infant Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hero Institute of Infant Nutrition</name>
      <address>
        <city>Alcantarilla</city>
        <state>Murcia</state>
        <zip>30820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murcia University</name>
      <address>
        <city>Espinardo</city>
        <state>Murcia</state>
        <zip>30071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granada University</name>
      <address>
        <city>Granada</city>
        <zip>18100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valencia University</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.hero.es</url>
    <description>Hero Institute of Infant Nutrition</description>
  </link>
  <reference>
    <citation>Sierra S, Lara-Villoslada F, Sempere L, Olivares M, Boza J, Xaus J. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe. 2010 Jun;16(3):195-200. doi: 10.1016/j.anaerobe.2010.02.001. Epub 2010 Feb 14.</citation>
    <PMID>20159049</PMID>
  </reference>
  <reference>
    <citation>Wind RD, Tolboom H, Klare I, Huys G, Knol J. Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers. Br J Nutr. 2010 Dec;104(12):1806-16. doi: 10.1017/S0007114510002746. Epub 2010 Aug 9.</citation>
    <PMID>20691131</PMID>
  </reference>
  <reference>
    <citation>de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr. 2005 Aug;24(4):481-91. Epub 2005 Apr 21.</citation>
    <PMID>16054520</PMID>
  </reference>
  <reference>
    <citation>Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol. 2008 Apr 7;14(13):2029-36.</citation>
    <PMID>18395902</PMID>
  </reference>
  <reference>
    <citation>Ouwehand AC, Bergsma N, Parhiala R, Lahtinen S, Gueimonde M, Finne-Soveri H, Strandberg T, Pitk√§l√§ K, Salminen S. Bifidobacterium microbiota and parameters of immune function in elderly subjects. FEMS Immunol Med Microbiol. 2008 Jun;53(1):18-25. doi: 10.1111/j.1574-695X.2008.00392.x. Epub 2008 Mar 10.</citation>
    <PMID>18336547</PMID>
  </reference>
  <reference>
    <citation>Klein A, Friedrich U, Vogelsang H, Jahreis G. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults. Eur J Clin Nutr. 2008 May;62(5):584-93. Epub 2007 Apr 18.</citation>
    <PMID>17440520</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>August 19, 2014</results_first_submitted>
  <results_first_submitted_qc>September 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hero Institute for Infant Nutrition</investigator_affiliation>
    <investigator_full_name>Pedro Abellan</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Immunity</keyword>
  <keyword>Gastrointestinal symptoms</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Volunteers are given strain CNCM I-4034.
Probiotic CNCM I-4034: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Volunteers receive Probiotic CNCM I-4035.
Probiotic CNCM I-4035: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Volunteers are given Probiotic CNCM I-4036.
Probiotic CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
Probiotics CNCM I-4035 and CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="P5">
          <title>Group E</title>
          <description>Volunteers receive a placebo.
Placebo capsule: Placebo capsule for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The average age was 28 years in all groups. Gender male/female in Probiotic groups 37/43 and placebo groups 9/11. Regi√≥n of enrollment were Granada, Murcia and Valencia cities placed in southeast of Spain.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Volunteers are given strain CNCM I-4034.
Probiotic CNCM I-4034: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Volunteers receive Probiotic CNCM I-4035.
Probiotic CNCM I-4035: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Volunteers are given Probiotic CNCM I-4036.
Probiotic CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
Probiotics CNCM I-4035 and CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Group E</title>
          <description>Volunteers receive a placebo.
Placebo capsule: Placebo capsule for 28 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="5"/>
                    <measurement group_id="B2" value="27" spread="5.7"/>
                    <measurement group_id="B3" value="29.4" spread="7.1"/>
                    <measurement group_id="B4" value="30.3" spread="7.6"/>
                    <measurement group_id="B5" value="28.5" spread="7.6"/>
                    <measurement group_id="B6" value="28.78" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Tolerance After Probiotic Consumption.</title>
        <description>Tolerance of these probiotic strains was determined using the gastrointestinal symptom rating scale (GSRS), daily recorded gastrointestinal symptoms and defecation frequency.Intolerance was defined as a symptom score of 2 or higher on the GSRS. The unit of measure is the &quot;number of participants&quot; was tolerant to the intervention.</description>
        <time_frame>4 weeks of the treatments. Daily recorded.</time_frame>
        <population>Calculation of simple size was based on the variance in the probiotic strain count (log strain CFU/g) in feces and a difference of 25% compared with the placebo. alfa: 0.05 power 90%</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Volunteers are given strain CNCM I-4034.
Probiotic CNCM I-4034: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Volunteers receive Probiotic CNCM I-4035.
Probiotic CNCM I-4035: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Volunteers are given Probiotic CNCM I-4036.
Probiotic CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
Probiotics CNCM I-4035 and CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group E</title>
            <description>Volunteers receive a placebo.
Placebo capsule: Placebo capsule for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Tolerance After Probiotic Consumption.</title>
          <description>Tolerance of these probiotic strains was determined using the gastrointestinal symptom rating scale (GSRS), daily recorded gastrointestinal symptoms and defecation frequency.Intolerance was defined as a symptom score of 2 or higher on the GSRS. The unit of measure is the &quot;number of participants&quot; was tolerant to the intervention.</description>
          <population>Calculation of simple size was based on the variance in the probiotic strain count (log strain CFU/g) in feces and a difference of 25% compared with the placebo. alfa: 0.05 power 90%</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastrointestinal and Immune Effects of Probiotics Consumption.</title>
        <description>Effect on the systemic and adaptive immune system. This will be measured by means of lymphocite populations and plasma cytokine present on blood, IgAs on serum (at zero time and after four weeks of treatment), IgAs on saliva and faeces and AGCC (at zero time and after four weeks and two more weeks).
Gastrointestinal effects will be measured by means of gastrointestinal symptoms record and frequency and aspect of faeces, during the treatment and the following two weeks (wash-out period).</description>
        <time_frame>At Time zero, after 4 weeks, and 2 later.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the first washout (15 days) intervention period (28 days) and second wasout period (15 days). The assessment was performed using Gastrointestinal Symptom Rating Scale questionnaire (GSRS)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Volunteers are given strain CNCM I-4034.
Probiotic CNCM I-4034: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Volunteers receive Probiotic CNCM I-4035.
Probiotic CNCM I-4035: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Volunteers are given Probiotic CNCM I-4036.
Probiotic CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
Probiotics CNCM I-4035 and CNCM I-4036: 9x10E9 cfu (colony forming unit) per day during 28 days.</description>
        </group>
        <group group_id="E5">
          <title>Group E</title>
          <description>Volunteers receive a placebo.
Placebo capsule: Placebo capsule for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain, nausea and vomiting, hard stools, acid regurgitation, eructation...</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Esther Matencio Hilla</name_or_title>
      <organization>Hero Institute for Infant Nutrition</organization>
      <phone>+0034 968 89 89 00</phone>
      <email>esther.matencio@hero.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

